Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better healthspiriva® respimat® Soft Mist Inhaler,which delivers tiotropium via a soft mistcloud, successfully secures Europeanregistration in 25 member states.GOLD update recommends longactinganticholinergics such asspiriva® for every patient requiringmaintenance therapy.spiriva® has over 31 millionpatient-years ofextensive real-worldexperience.UPLIFT® demonstrates thatspiriva® sustains lung functionimprovements over four years andimproves survival rate.POET-COPD® study results demonstratethe superiority of spiriva®over salmeterol in reducing the riskof COPD exacerbations.spiriva® is currently availablein over 120 countries and continuesto be the most widelyprescribed maintenance therapyfor COPD worldwide.2007 2008 2009 201020112012 and beyondConfirmed value to the patientAmong external institutions conductinghealth technology assessments(HTAs), the German IQWiG (Institutefor Quality and Efficiency in HealthCare) has examined whether spiriva®offers a perceptible benefit to patientscompared with placebo and other COPDdrugs. The IQWiG considers it proventhat, in comparison with the group oflong-acting beta-agonists (salmeterol,formoterol and indacaterol), tiotropiumdelivered via the HandiHaler® exhibitsadditional benefit in terms of both exacerbationfrequency and the need forhospitalisation as a result of exacerbation.A “proof” of evidence is the highestIQWiG evidence grading possible.COMBIVENT® RESPIMAT® in the USAFollowing FDA approval in 2011,combivent® respimat® was launchedin the US market in 2012. This marksan important milestone, as it is the firstproduct to be delivered in the propellant-freeand innovative respimat® inhaler.The respimat® inhaler is a newgeneration inhaler with a unique deliverymechanism, which is preferred bypatients. It is the platform for our futurerespiratory products.COMBIVENT® RESPIMAT®The launch of combivent®respimat® for COPD in 2012was the first introduction of therespimat® inhaler on theUS market.The IQWiG assessment was largelybased upon the head-to-head POET-COPD® study, comparing the effects onacute worsening of the disease (exacerbations)of two long-acting bronchodilatorsspiriva® and salmeterol. The studyshowed significantly better outcomeswith spiriva® in reducing COPD exacerbationscompared with salmeterol.The true face of COPD 81